Effects of Weekly or Intermittent Dosing Regimens of Signaling Pathway Inhibitors
Project Number261201200013I-0-26100007-2
Contact PI/Project LeaderDAVIS, TERISA
Awardee Organization
Description
Abstract Text
This task order is designed to determine the relative effectiveness (as cancer chemopreventive agents) of EGFr, MEK, and PI3K inhibitors administered on various schedules. This information will be used as a guide in designing clinical trials of these agents.
No Sub Projects information available for 261201200013I-0-26100007-2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 261201200013I-0-26100007-2
Patents
No Patents information available for 261201200013I-0-26100007-2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 261201200013I-0-26100007-2
Clinical Studies
No Clinical Studies information available for 261201200013I-0-26100007-2
News and More
Related News Releases
No news release information available for 261201200013I-0-26100007-2
History
No Historical information available for 261201200013I-0-26100007-2
Similar Projects
No Similar Projects information available for 261201200013I-0-26100007-2